CONCORDBIO
CONCORD BIOTECH LIMITED
Each stock's 10,000-path forecast, rendered as light.
CONCORD BIOTECH LIMITED (CONCORDBIO) Stock Analysis & Case Study
Is CONCORDBIO a good buy? The data-driven verdict.
CONCORD BIOTECH LIMITED (CONCORDBIO) trades at ₹1,365,on the numbers it tread carefully, a Downstox Snapshot Score of 36/100.
On the numbers, CONCORD BIOTECH LIMITED (CONCORDBIO) tread carefully, a Downstox Snapshot Score of 36/100, weighing expensive at 51.4× earnings, ROE of 12.5%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
CONCORDBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How CONCORDBIO ranks against the 2,373 companies in our screener
- CONCORDBIO's market cap of 14,280 Cr ranks in the 80th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CONCORDBIO's book value of ₹193 ranks in the 71st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CONCORDBIO's promoter holding of 44.1% ranks in the 21st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CONCORDBIO's 3-year revenue growth of 7.0% ranks in the 41st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold 3-year profit (PAT) growth or debt-to-equity ratio figures for CONCORDBIO, as of 9 Aug 2026, so those are not ranked here.
Is CONCORDBIO overvalued? CONCORDBIO P/E vs peers
CONCORDBIO trades at 51.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
CONCORDBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.9y of CONCORDBIO history (13%/yr drift, 45%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| CONCORDBIO 2027 | ₹765 | ₹1,373 | ₹2,462 | +1% |
| CONCORDBIO 2028 | ₹618 | ₹1,381 | ₹3,086 | +1% |
| CONCORDBIO 2029 | ₹513 | ₹1,389 | ₹3,758 | +2% |
| CONCORDBIO 2030 | ₹438 | ₹1,397 | ₹4,458 | +2% |
| CONCORDBIO 2031 | ₹383 | ₹1,405 | ₹5,155 | +3% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability CONCORDBIO goes up, or doubles?
The bull case for CONCORDBIO
- CONCORDBIO's return on equity of 12.5% ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,758.
The bear case & risks
- CONCORDBIO's P/E of 51.4x is lower than 26% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹513.
CONCORDBIO volatility & expected range, how bumpy is the ride?
Over the last 2.9 years CONCORDBIO compounded at 13%/year with annualized volatility of 45%. That volatility implies a 1-year 80% range of ₹765-₹2,462, the honest backbone behind any single price target.
CONCORDBIO price forecast, the full 60-month probability fan
CONCORDBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds CONCORDBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the CONCORDBIO price target & forecast page.
CONCORDBIO Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. CONCORDBIO scores 5/8, mixed financial health.
CONCORDBIO MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy CONCORDBIO with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 34.58% | 2.9× |
| ZerodhaCHEAPEST | 34.54% | 2.9× |
| Groww | 34.72% | 2.9× |
| Dhan | 34.54% | 2.9× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 34.72% | 2.9× |
| Pocketful | 34.65% | 2.9× |
| Anand RathiCHEAPEST | 34.54% | 2.9× |
| Bajaj Broking | 40.00% | 2.5× |
| Share India | 34.68% | 2.9× |
Compare every broker on the CONCORDBIO MTF page.
About CONCORD BIOTECH LIMITED: sector, index & market-cap context
CONCORD BIOTECH LIMITED (CONCORDBIO) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹14,280 Cr. See more stocks on our screener.
How the CONCORDBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of CONCORD BIOTECH LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CONCORDBIO analysis, FAQs
Is CONCORD BIOTECH LIMITED (CONCORDBIO) a good buy?
On the numbers, CONCORD BIOTECH LIMITED (CONCORDBIO) tread carefully, a Downstox Snapshot Score of 36/100, weighing expensive at 51.4× earnings, ROE of 12.5%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is CONCORDBIO overvalued or undervalued?
CONCORDBIO trades at 51.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the CONCORDBIO share price target for 2031?
CONCORDBIO's probability-weighted 2031 median target is ₹1,405, with an 80% range of ₹383-₹5,155 (10,000-path Monte-Carlo).
What is the probability CONCORDBIO doubles in 5 years?
The modelled probability of CONCORDBIO reaching ₹2,730 (2×) within 5 years is 26%.
What is the bull case for CONCORDBIO?
CONCORDBIO's return on equity of 12.5% ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in CONCORDBIO?
CONCORDBIO's P/E of 51.4x is lower than 26% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.